- The FDA has expanded the EUA for Pfizer’s COVID-19 vaccine in adolescents based on the data from the P- III trial in 2,260 participants aged 12-15yrs. which showed 100% efficacy and was well-tolerated. The submission of data in children aged 6mos.- 2yrs. are expected in Q4’21
- The companies have submitted the data in adolescents for peer review and also submitted to EMA and other global regulators, expected in coming wks.
- Additionally, the ongoing pediatric study evaluating the safety and efficacy of COVID-19 vaccine in children aged 6mos. to 11 yrs. The companies plan to submit for a EUA or conditional marketing authorizations in children aged 2-5 yrs. and 5-11yrs. in Sept’2021
Click here to read full press release/ article | Ref: BUSINESS WIRE | Image: Pfizer